Company: PFSA
Filing Date: 2025-04-03
Form Type: S-4/A
Source: 0001213900-25-028544
Chunk: 460

Company: Profusa, Inc.
Filing Date: 2025-04-03
Form: S-4/A
Chunk 460
---
 six months’ base salary plus a pro -rataportion of any earned bonus payment (in a lump sum payment), as well as pay his monthly COBRA premiums for up to six months, subject to Dr. Hwang’s execution of a release of claims in favor of Profusa. 401(k) Plan Profusa maintains a qualified 401(k) savings plan which allows participants to defer a portion of their compensation to the 401(k) savings plan on a before -taxand after -taxbasis. Profusa provides discretionary profit sharing contributions on behalf of its eligible participants. Profusa did not make any profit sharing contributions in 2024. Director Compensation Profusa’s historical director compensation program has consisted of equity awards. However, in 2024, Profusa did not grant any equity awards to its non -employeedirectors and did not pay any cash director fees or other compensation to its non -employeedirectors. As of December 31, 2024, the non -employeedirectors held outstanding options to purchase Profusa shares as follows: Joan Braddi — 80,000shares. As Profusa’s Chief Executive Officer, Dr. Hwang does not receive any additional compensation for his service on the Profusa board of directors. Please see the 2024 Summary Compensation Table for the compensation paid or awarded to Dr. Hwang in 2024. 258 PROFUSA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis provides information that Profusa, Inc.’s (hereafter referred to as Profusa or we) management believes is relevant to an assessment and understanding of Profusa’s results of operations and financial condition. The discussion should be read together with “Selected Historical Financial and Operating Data of Profusa,” the historical audited annual statements for the years ended December 31, 2024 and 2023, and the related notes that are included elsewhere in this proxy statement/prospectus. The discussion and analysis should also be read together with the pro forma financial information as of and for the years ended December 31, 2024 and 2023. See “Unaudited Pro Forma Condensed Combined Financial Information.” This discussion may contain forward -looking statements based upon current expectations that involve risks and uncertainties. Profusa’s actual results may differ materially from those anticipated in these forward -looking statements as a result of various factors, including those set forth under “Risk Factors” or in other parts of this proxy